Cannabis
Research: Long-term use of cannabis has no effect on age-related cognitive abilities
A recent study conducted by researchers in Israel shows that long time cannabis use does not affect cognitive abilities in humans.As part of the study on the effect of cannabis on the brain, researchers analysed cognitive abilities of 63 people. All participants in the study had long been medical cannabis consumers and were compared to 62 non-cannabis individuals for the purpose of the study.
One of the most common stereotypes about cannabis is that long-term cannabis use damages the brain. Cannabis consumers have for decades been portrayed by mainstream media, television, and film as less intelligent than everyone else, and low levels of intelligence are a direct result of cannabis consumption. That has been repeatedly refuted by scientific research.
Worse still, this stereotype has been perpetuated by the negative propaganda that opponents of cannabis have been spreading for many decades. This harmful stereotype still exists in the minds of many people. Fortunately, scientific research has already refuted this thesis more than once.
Cannabis law reform and the legal cannabis industry spreading around the world show the truths about cannabis and those who consume it.
Consumers and patients around the world consistently break the stigma of cannabis and destroy long-held stereotypes. The fact is that – many very intelligent people consume cannabis – and this has probably been the case since people started to consume cannabis. Science shows that cannabis can be good for the human brain or at least harmless, as reflected in a recent study carried out in a country that has been researching the medical uses and effects of cannabis for decades – in Israel.
Read more about the study on cannabis conducted by scientists in Israel and find the most important cannabis news with the Hemp.im mobile app.
Cognitive abilities in adults
As part of a study on the effect of cannabis on the brain, Israeli researchers analysed cognitive abilities of 63 people. All participants in the study had long been medical cannabis consumers and were compared to 62 non-Hannabis individuals for the purpose of the study.
All participants in the study reported chronic pain and the average age of participants was 61. Participants were subjected to various cognitive tests to assess their memory, response time and ability to absorb new information.
Brain function naturally deteriorates with age, and some cannabis opponents claim that cannabis can accelerate the aging process. However, this is not what researchers have discovered.
Scientists’ conclusions
The researchers found ‘no significant differences in cognitive function’ between a group of cannabis consumers and a group of non-consumers.
“No significant differences in cognitive performance were found between cannabis users and non-consumers in the group of people with neuropathic pain. Evidence of this lack of relationship was stable,” – summarized the authors of the study.
“Furthermore, no significant links were found between different aspects of medical cannabis use patterns, including THC / CBD concentration, frequency and length of use, dosage and length of abstinence and cognitive ability. Moreover, both licensed and unlicensed patients with medical cannabis use obtained results relatively similar to those of a population without chronic pain,” said the researchers.
The authors also stated that “greater acceptance of cannabis, in addition to increasing life expectancy, will result in an increase in the number of middle-aged and elderly people who use cannabis for a long time. Given the growing evidence of the efficacy of cannabis use in many common conditions in the elderly, the absence of adverse effects on the brain with the current number of people over 50 years of age with chronic pain may contribute to a better assessment of the risks and benefits of cannabis treatment in this population.”
__
(Featured image by DimStock via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in FAKTY KONOPNE.PL, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Crypto1 week ago
Ripple Custody: How the XRP Company Wants to Offer Services for Banks
-
Fintech2 days ago
Global66 Reports Payments to Freelancers of Over $8 Million on Its Platform
-
Fintech6 days ago
Fintech Company Sonect Wants to Supply Europe with Cash
-
Biotech2 weeks ago
Vytrus Biotech Reports Its Best Quarter: Record Revenue and Rising EBITDA